Cold flow modelling of char concentration in the recirculated bed material stream of a dual fluidized bed steam gasification system

The dual fluidized bed (DFB) steam gasification technology of biomass was developed at Vienna University of Technology and is well-established for transforming biomass into a product gas which can be used for further applications. The DFB steam gasification reactor consists of a gasification chamber (bubbling bed, fluidized with steam) and a combustion chamber (turbulent bed, fluidized with air). Biomass is fed into the gasification chamber and gets in contact with the bed material, typically Olivine, at about 840°C. The released volatiles leave the gasification reactor as product gas. A part of the solid residue, called char, flows with the bed material via a chute to the combustion chamber where it is burnt with air. The bed material is heated up, separated from the flue gas stream in a cyclone and flows back to the gasification reactor via a loop seal where it provides the heat for devolatilization and drying of the biomass. The movement of the char is crucial since a sufficient amount has to flow to the combustion chamber and burn to provide enough energy for bed material heat-up. Up to now little is known about the char concentration in the bed material recirculation stream (or short recirculation stream) and its influencing variables. Therefore, a cold flow model, operated with ambient air, was constructed to study the influence of various parameters on the char concentration in the recirculation stream. Bronze is used as bed material since is matches closest to the scaling criteria. The char is also scaled; polyethylene is used as model char. The cold flow model, see Figure 1 for the flowsheet, consists of a “gasification chamber” which corresponds to the gasification chamber in the hot plant and is as well operated as a bubbling bed. Via a chute the recirculation stream moves to a rotary valve which enables to set a fixed recirculation rate and make it independent from the following pneumatic conveying. Then, gas and solids are separated in a cyclone and the recirculation stream finally flows back to the gasification chamber. After the loop seal samples are taken for investigation of the model char concentration in the recirculation stream. In the present study the influence of fluidization rate in the gasification chamber, bed material recirculation rate and model char mass in the system on the char concentration in the recirculation stream are investigated. It was found that the model char particles show a flotsam behavior. Higher fluidization rates increase the model char concentration in the recirculation stream because of better mixing, whereas the bed material recirculation rate has only little influence. Doubling and tripling the overall char mass in the system did not lead to a doubling or tripling model char concentration in the recirculation stream. The present observations are helping to better understand the ongoing phenomena inside of the dual fluidized bed gasification reactor and provide knowledge to further optimize it. Please click Additional Files below to see the full abstract

On state-alternating context-free grammars

AbstractState-alternating context-free grammars are introduced, and the language classes obtained from them are compared to the classes of the Chomsky hierarchy as well as to some well-known complexity classes. In particular, state-alternating context-free grammars are compared to alternating context-free grammars (Theoret. Comput. Sci. 67 (1989) 75–85) and to alternating pushdown automata. Further, various derivation strategies are considered, and their influence on the expressive power of (state-) alternating context-free grammars is investigated

Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and

Five years of adjuvant tamoxifen has been the standard endocrine treatment for early-stage breast cancer for several decades. Adjuvant endocrine therapy following primary surgery for breast cancer reduces the risk of recurrence and increases overall survival beyond the period of treatment for women with estrogen receptor (ER) -positive disease ( 1 ). Mature meta-analysis data on 15-year recurrence and breast cancer mortality probabilities demonstrate substantial and persistent benefits of receiving adjuvant tamoxifen compared with no adjuvant treatment ( 1 ). Most of the effect of adjuvant tamoxifen on recurrence is seen during the first 5 years after surgery, when tamoxifen is generally still administered, with gains in recurrence-free survival of 11.4%. However, many women who are treated with 5 years of adjuvant tamoxifen still develop recurrent disease, and most of the effect of adjuvant tamoxifen on breast cancer mortality occurs after the fifth year after surgery

CO2 capture from syngas by an adsorption process at a biomass gasification CHP plant: Its comparison with amine-based CO2 capture

AbstractAn exemplary 10MWth biomass-fuelled CHP plant equipped with a FICFB (Fast Internally Circulating Fluidised Bed) gasifier and a Jenbacher type 6 gas engine was simulated using Honeywell UniSim R400 to estimate the power and thermal outputs. The biomass gasification CHP plant was integrated with either a pre-combustion adsorptive capture process or a conventional post-combustion amine process to achieve carbon-negative power and heat generation. The practical maximum of carbon capture rate achievable with an adsorptive CO2 capture process applied to a syngas stream was 49% in overall while the amine process could boost the carbon capture rate up to 59%. However, it was found that the two-stage, two-bed PVSA (Pressure Vacuum Swing Adsorption) unit would have a clear advantage over the conventional amine processes in that the CHP plant integrated with the PVSA unit could achieve 1.7% points higher net electrical efficiency and 12.8% points higher net thermal efficiency than the CHP plant integrated with the amine process

Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and

Five years of adjuvant tamoxifen has been the standard endocrine treatment for early-stage breast cancer for several decades. Adjuvant endocrine therapy following primary surgery for breast cancer reduces the risk of recurrence and increases overall survival beyond the period of treatment for women with estrogen receptor (ER) -positive disease ( 1 ). Mature meta-analysis data on 15-year recurrence and breast cancer mortality probabilities demonstrate substantial and persistent benefits of receiving adjuvant tamoxifen compared with no adjuvant treatment ( 1 ). Most of the effect of adjuvant tamoxifen on recurrence is seen during the first 5 years after surgery, when tamoxifen is generally still administered, with gains in recurrence-free survival of 11.4%. However, many women who are treated with 5 years of adjuvant tamoxifen still develop recurrent disease, and most of the effect of adjuvant tamoxifen on breast cancer mortality occurs after the fifth year after surgery

TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients

We investigated the hypothesis that the varying treatment efficacy of adjuvant 5-fluorouracil (5FU) in stage III colon cancer is linked to the TP53 mutational status. ABCSG-90 was a prospective randomized trial in which effect of adjuvant 5FU was studied in stage III colon cancer patients. Tumor material of 70% of these patients (389/572) was available for analysis of the biomarker TP53 using a TP53-gene-specific Sanger sequencing protocol. Median follow-up was 88 months. TP53 mutation frequency was 33%. A significant interaction between TP53 status, outcomes and nodal category was found (P = 0.0095). In the N1 category, TP53 wildtype patients had significantly better overall survival than TP53 mutated (81.0% vs. 62.0% overall survival at 5 years; HR = 2.131; 95% CI: 1.344–3.378; P = 0.0010). In the N2 category, the TP53 status did not affect survival (P = 0.4992). In TP53 wildtype patients, the prognostic significance of N category was significantly enhanced (P = 0.0002). In TP53 mutated patients, survival curves of N1 and N2 patients overlapped and nodal category was no longer prognostic. The biomarker TP53 independently predicted effect of adjuvant 5FU in N1 colon cancer patients. TP53 was not predictive in N2 patients, in whom 5FU is known to have no effect